Agonistic anti-tumor necrosis factor receptor 2 antibodies
US-2019135929-A1 · May 9, 2019 · US
Anti-TNFR2 antibodies and uses thereof
US12435151B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12435151-B2 |
| Application number | US-202017434340-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 28, 2020 |
| Priority date | Mar 1, 2019 |
| Publication date | Oct 7, 2025 |
| Grant date | Oct 7, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases.
First claim
Opening claim text (preview).
We claim: 1. An isolated antibody which binds to human TNFR2 comprising heavy and light chain CDRs of the heavy and light chain variable region pairs of SEQ ID NOs: 117 and 118, respectively. 2. The isolated antibody of claim 1 , comprising: heavy chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 105-107, respectively; and light chain CDR1, CDR2, and CDR3 sequences comprising SEQ ID NOs: 108-110, respectively. 3. The isolated…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12435151B2 cover?
- Disclosed herein are anti-TNFR2 antibodies, therapeutic compositions comprising the anti-TNFR2 antibodies, and methods of using such antibodies and compositions in the treatment of cancer and autoimmune diseases.
- Who is the assignee on this patent?
- Merrimack Pharmaceuticals Inc, Univ California
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2878. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).